Novartis AG chief executive Vas Narasimhan said his Sandoz generics unit’s malaria, lupus and arthritis drug hydroxychloroquine is the company’s biggest hope against COVID-19, Swiss weekly SonntagsZeitung reported yesterday.
Novartis has pledged to donate 130 million doses and is supporting clinical trials needed before the medicine, which US President Donald Trump also has been promoting, can be approved for use.
Other companies including Bayer AG and Teva Pharmaceutical Industries Ltd have also agreed to donate hydroxychloroquine or similar drugs, while Gilead Sciences Inc is testing its experimental drug remdesivir against COVID-19.
“Pre-clinical studies in animals, as well as the first data from clinical studies, show that hydroxychloroquine kills the coronavirus,” Narasimhan told the newspaper. “We’re working with Swiss hospitals on possible treatment protocols for the clinical use of the drug, but it’s too early to say anything definitively.”
He said the company is currently looking for additional active drug ingredients to make more hydroxychloroquine, should clinical trials be successful.
Narasimhan said that three other Novartis drugs — Jakavi for cancer, multiple sclerosis drug Gilenya and fever drug Ilaris — are being studied for their effect on complications related to COVID-19, SonntagsZeitung reported.
This follows efforts to repurpose drugs made by Roche Holding AG and Sanofi SA to treat complications related to the disease.
Meanwhile, Gilead is to expand access to its experimental anti-coronavirus drug remdesivir to accelerate its emergency use for multiple severely ill patients.
The drugmaker said it is switching to “expanded access” from a “compassionate use” program under which remdesivir was given to more than 1,000 COVID-19 patients.
“With expanded access, hospitals or physicians can apply for emergency use of remdesivir for multiple severely ill patients at a time,” Gilead chairman and CEO Daniel O’Day said in an open letter sent by e-mail on Saturday.
“While it will take some time to build a network of active sites, this approach will ultimately accelerate emergency access for more people,” he said.
Remdesivir was developed initially for Ebola and studied in patients in the eastern region of the Democratic Republic of the Congo. Multiple clinical trials are investigating the drug’s effects in COVID-19 patients in China and elsewhere.
Initial results might be reported in the coming weeks, O’Day said.
If approved, the Foster City, California-based company “will work to ensure affordability and access, so that remdesivir is available to patients with the greatest need,” he said.
“The urgency comes from knowing the desperate need among patients and the lack of any approved treatment,” O’Day said. “The responsibility is to ensure that remdesivir, an investigational medicine, is effective and safe before it is distributed for use worldwide,” he said.
Additional reporting by Bloomberg
DECOUPLING? In a sign of deeper US-China technology decoupling, Apple has held initial talks about using Baidu’s generative AI technology in its iPhones, the Wall Street Journal said China has introduced guidelines to phase out US microprocessors from Intel Corp and Advanced Micro Devices Inc (AMD) from government PCs and servers, the Financial Times reported yesterday. The procurement guidance also seeks to sideline Microsoft Corp’s Windows operating system and foreign-made database software in favor of domestic options, the report said. Chinese officials have begun following the guidelines, which were unveiled in December last year, the report said. They order government agencies above the township level to include criteria requiring “safe and reliable” processors and operating systems when making purchases, the newspaper said. The US has been aiming to boost domestic semiconductor
Nvidia Corp earned its US$2.2 trillion market cap by producing artificial intelligence (AI) chips that have become the lifeblood powering the new era of generative AI developers from start-ups to Microsoft Corp, OpenAI and Google parent Alphabet Inc. Almost as important to its hardware is the company’s nearly 20 years’ worth of computer code, which helps make competition with the company nearly impossible. More than 4 million global developers rely on Nvidia’s CUDA software platform to build AI and other apps. Now a coalition of tech companies that includes Qualcomm Inc, Google and Intel Corp plans to loosen Nvidia’s chokehold by going
ENERGY IMPACT: The electricity rate hike is expected to add about NT$4 billion to TSMC’s electricity bill a year and cut its annual earnings per share by about NT$0.154 Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) has left its long-term gross margin target unchanged despite the government deciding on Friday to raise electricity rates. One of the heaviest power consuming manufacturers in Taiwan, TSMC said it always respects the government’s energy policy and would continue to operate its fabs by making efforts in energy conservation. The chipmaker said it has left a long-term goal of more than 53 percent in gross margin unchanged. The Ministry of Economic Affairs concluded a power rate evaluation meeting on Friday, announcing electricity tariffs would go up by 11 percent on average to about NT$3.4518 per kilowatt-hour (kWh)
OPENING ADDRESS: The CEO is to give a speech on the future of high-performance computing and artificial intelligence at the trade show’s opening on June 3, TAITRA said Advanced Micro Devices Inc (AMD) chairperson and chief executive officer Lisa Su (蘇姿丰) is to deliver the opening keynote speech at Computex Taipei this year, the event’s organizer said in a statement yesterday. Su is to give a speech on the future of high-performance computing (HPC) in the artificial intelligence (AI) era to open Computex, one of the world’s largest computer and technology trade events, at 9:30am on June 3, the Taiwan External Trade Development Council (TAITRA) said. Su is to explore how AMD and the company’s strategic technology partners are pushing the limits of AI and HPC, from data centers to